ThromboGenics NV of Belgium has opened a new headquarters in the US ahead of the filing of a biologics license application with the Food and Drug Administration for its treatment of an eye disorder known as symptomatic vitreomacular adhesion. ---Subscribe to MedNous to access this article--- Company News
